Latent tuberculosis infection: recent progress and challenges in South Korea.

The Korean Journal of Internal Medicine
Doosoo Jeon

Abstract

Management of latent tuberculosis infection (LTBI) is a critical element in the elimination of tuberculosis (TB). However, the low positive predictive value of the current diagnostic tests and the low acceptance and completion rate of the isoniazid- based regimen are major barriers to the implementation and scale-up of programmatic management of LTBI. In the past decade, there has been some progress in the conception, diagnosis, and treatment of LTBI. LTBI is now understood as a dynamic spectrum rather than the traditional binary distinction between active and latent TB. New insight into LTBI has led to a renewed interest in incipient TB, which would be a potential target for developing new diagnostics and therapeutics of LTBI. Recent studies showed that host transcriptomic signatures could be a potential biomarker for incipient TB. The new shorter rifamycin-based regimens have shown comparable efficacy, but better completion rate and safety compared to the isoniazid-based regimen. In South Korea, LTBI management has been expanded and integrated into key elements of the National Tuberculosis Control Program. For the programmatic approach to LTBI management, the following challenges need to be addressed; target group selection, ...Continue Reading

References

Feb 1, 1974·American Journal of Epidemiology·G W ComstockS F Woolpert
Dec 1, 1995·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·S J KimE G Lee
Oct 27, 2009·Nature Reviews. Microbiology·Clifton E BarryDouglas Young
Oct 26, 2011·The Journal of Infectious Diseases·Jacqueline M Achkar, Elizabeth R Jenny-Avital
Dec 27, 2011·Drug Discovery Today·Hanif EsmailRobert J Wilkinson
Dec 19, 2012·Annual Review of Public Health·Christopher DyeMario Raviglione
Mar 31, 2015·Lancet·Mukund UplekarUNKNOWN WHO's Global TB Programme
Dec 2, 2015·The European Respiratory Journal·Alberto MatteelliMario Raviglione
Jun 1, 2016·AIDS·Timothy R SterlingUNKNOWN Tuberculosis Trials Consortium, the AIDS Clinical Trials Group for the PREVENT TB Trial (TBTC Study 26ACTG 5259) The investi
Jan 15, 2018·Tuberculosis and Respiratory Diseases·Hyung Woo Kim, Ju Sang Kim
Feb 20, 2018·Respirology : Official Journal of the Asian Pacific Society of Respirology·Delia GolettiTom H M Ottenhoff
Mar 13, 2018·Tuberculosis and Respiratory Diseases·Jae Kyoung KimJoon Sung Joh
Apr 7, 2018·American Journal of Respiratory and Critical Care Medicine·Sara SulimanUNKNOWN GC6-74 cohort study team, The ACS cohort study team
May 16, 2018·American Journal of Epidemiology·Nicolas A MenziesJoshua A Salomon
Jul 20, 2018·Clinical Microbiology Reviews·Paul K DrainDavid R Sherman
Aug 2, 2018·The New England Journal of Medicine·Dick MenziesAndrea Benedetti
Aug 8, 2018·Epidemiology and Health·Kyung Sook Cho
Oct 12, 2018·Tuberculosis and Respiratory Diseases·Sangyoon LeeDae Hwan Kim
Feb 12, 2019·Journal of Preventive Medicine and Public Health = Yebang Ŭihakhoe Chi·Dae Soon Kim, Jong-Myon Bae
Mar 7, 2019·Tuberculosis and Respiratory Diseases·Hyunwoo KimHongjo Choi
Mar 14, 2019·The New England Journal of Medicine·Susan SwindellsUNKNOWN BRIEF TB/A5279 Study Team
Apr 17, 2019·PLoS Medicine·Adam Penn-NicholsonUNKNOWN ACS and GC6–74 cohort study groups
Jun 7, 2019·PLoS Medicine·Jonathon R CampbellKevin Schwartzman
Jun 7, 2019·Tuberculosis and Respiratory Diseases·Beong Ki KimSeung Heon Lee
Jul 4, 2019·Tuberculosis and Respiratory Diseases·Seung Heon Lee
Sep 2, 2019·The Journal of Infection·Giovanni SotgiuDelia Goletti
Oct 30, 2019·The New England Journal of Medicine·Dereck R TaitFrançois Roman
Apr 11, 2018·Journal of Clinical Tuberculosis and Other Mycobacterial Diseases·Unyeong GoUNKNOWN Korea Tuberculosis Epidemic Investigation Service
Nov 17, 2019·Clinics in Chest Medicine·Michelle K Haas, Robert W Belknap
Dec 27, 2019·The Korean Journal of Internal Medicine·Soo Han KimTae Sun Shim

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Software Mentioned

QuantiFERON
- TB Plus QFT
QFT
IGRA
- Plus
Plus
QFTGIT

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Related Papers

Canada Communicable Disease Report = Relevé Des Maladies Transmissibles Au Canada
S Kiazyk, T B Ball
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Alsdurf Hannah, Menzies Dick
Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin
Andreas SandgrenMarieke J van der Werf
© 2021 Meta ULC. All rights reserved